W. W. Parmley, M.D., Guest Editor
This supplement is based on the proceedings of a roundtable meeting held on November 8, 1998, sponsored by COR Therapeutics, Inc., and Key Pharmaceuticals, Inc.
To download the full supplement in PDF [260 kb], follow this link.
To read individual articles, follow the links below.
W. W. Parmley, M.D.
Trials of Glycoprotein IIb-IIIa Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndromes: Applicability to the Practice of Medicine in the United States [PDF]
M. Cohen, M.D., J. J. Ferguson III, M.D., R. A. Harrington, M.D.
The opinions expressed in this presentation are those of the panelists and are not attributable to the sponsor or the publisher, editor, or editorial board of Clinical Cardiology. Clinical judgment must guide each physician in weighing the benefits of treatment against the risk of toxicity. References made in the articles may indicate uses of drugs at dosages, for periods of time, and in combinations not included in the current prescribing information.